Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has issued an announcement.
CANbridge Pharmaceuticals Inc. has successfully completed the subscription of new shares under a general mandate, issuing nearly 10 million shares at a price of HK$2.26 each, generating gross proceeds of approximately HK$22.59 million. This strategic move, involving independent subscribers, is expected to bolster the company’s financial position and support its operational plans, enhancing its market presence and potentially benefiting stakeholders by expanding its capital base.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and targeted cancers. The company operates primarily in the global healthcare market, aiming to address unmet medical needs through its specialized products and services.
Average Trading Volume: 13,768,189
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.17B
See more data about 1228 stock on TipRanks’ Stock Analysis page.